This is not widely accepted, however, and retrospective data have demonstrated that ‘low risk’ FLT3-ITD AML, with FLT3-IT low AR and positive NPM1 mutational status, still conveys poor prognosis, with a 5-year OS of 41.3%, and OS is improved by HCT (139). The gene discussed is FLT3; the disease is acute myeloid leukemia.